Page 1

only For personal use Fisher & Paykel HEALTHCARE News Release STOCK EXCHANGE LISTINGS : NEW ZEALAND ( FPH ) , AUSTRALIA ( FPH ) Fisher & Paykel Healthcare announces result for the first half of the 2022 financial year Auckland , New Zealand , 25 November 2021 - Fisher & Paykel Healthcare Corporation Limited today announced its results for the first half of the 2022 financial year . For the six months ended 30 September 2021 , total operating revenue was $ 900 million . This was a 1 % decline from the same period in the previous financial year , or a 2 % increase in constant currency . Net profit after tax for the first half was $ 222 million , a 2 % decline from the prior comparable period , or a 1 % decline in constant currency . Managing Director and CEO Lewis Gradon said , “ For nearly two years now , our customers have been working selflessly to care for patients during a pandemic . Our people and our suppliers have also been working under demanding circumstances , and we are grateful for their relentless commitment . " As you may recall , the first half of the last financial year was a period of extraordinary demand during the initial surges of COVID - 19 . Our financial results in the first half of the 2022 financial year have continued to be very strong , " Mr Gradon continued . In the Hospital product group , which includes humidification products used in respiratory , acute and surgical care , revenue for the first half was $ 670 million , a decline of 2 % from the first half of the 2021 financial year , or an increase of 1 % in constant currency . Hospital consumables grew 8 % in constant currency , and of total Hospital product group revenue , 67 % was from the sale of consumables and 33 % was from the sale of hardware . In the Homecare product group , which includes products used in the treatment of obstructive sleep apnea ( OSA ) and respiratory support in the home , revenue was $ 227 million , a 0.3 % increase over the prior comparable period , or 3 % in constant currency . Gross margin was 63.1 % , up 135 basis points or 53 basis points in constant currency compared to the first half of the 2021 financial year . Elevated freight costs and air freight utilisation continued but were lower than the same period last year , impacting gross margin by approximately 190 basis points compared to pre - COVID - 19 levels . The company's directors have approved an interim dividend of 17 cents per ordinary share . The interim dividend , carrying full New Zealand imputation credit , will be paid on 15 December 2021 with a record date of 3 December 2021 . The company also announced that over the next five years it expects to invest approximately $ 700 million in land and buildings . This includes a fifth building completing its Auckland campus and acquiring land for a second New Zealand campus . Over the next five years the company expects to add an additional three manufacturing facilities located outside New Zealand , the first of which is currently under construction in Tijuana , Mexico . " The longer - term impact from COVID - 19 for our business has been a larger installed base of our hospital hardware and increased global physician awareness and experience with our therapies and products . To ensure we are well - positioned to meet demand for the ongoing use of this installed base of hardware and accommodate our strong new product pipeline , we are continuing to invest in our infrastructure to ensure it supports our long - term growth , ” said Mr Gradon . Given the continuing uncertainties associated with COVID - 19 , including the impact on hospitalisations and public and civic responses to COVID - 19 case numbers , the company is not providing quantitative revenue or earnings guidance for the remainder of the 2022 financial year .